Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients

Gun Min Kim, Young Sam Kim, Young Ae Kang, Jae Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Seung Taek Lim, Joo Hang Kim, Se Kyu Kim, Byoung Chul Cho

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin- derivative antitumor agent that belongsto the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safetyof belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). METHODS:: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS:: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%). CONCLUSION:: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.

Original languageEnglish
Pages (from-to)731-736
Number of pages6
JournalJournal of Thoracic Oncology
Volume7
Issue number4
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Small Cell Lung Carcinoma
Confidence Intervals
Disease-Free Survival
Survival
Topoisomerase Inhibitors
Camptothecin
belotecan
Neutropenia
Thrombocytopenia
Antineoplastic Agents
Anemia
Safety
Recurrence
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Kim, Gun Min ; Kim, Young Sam ; Ae Kang, Young ; Jeong, Jae Heon ; Kim, Sun Mi ; Hong, Yun Kyoung ; Sung, Ji Hee ; Lim, Seung Taek ; Kim, Joo Hang ; Kim, Se Kyu ; Cho, Byoung Chul. / Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. In: Journal of Thoracic Oncology. 2012 ; Vol. 7, No. 4. pp. 731-736.
@article{07db641c0fd9445388ecf16ebe7d26ef,
title = "Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients",
abstract = "INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin- derivative antitumor agent that belongsto the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safetyof belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). METHODS:: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS:: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68{\%}) and 2 in 16 patients (32{\%}). Twenty patients (40{\%}) had sensitive relapse and 30 patients (60{\%}) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20{\%} (95{\%} confidence interval [CI], 8-40), 2.8 months (95{\%} CI, 0.53-5.06), and 6.5 months (95{\%} CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10{\%} (95{\%} CI, 1-21), 1.5 months (95{\%} CI, 1.25-1.75), and 4.0 months (95{\%} CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54{\%}), thrombocytopenia (38{\%}), and anemia (32{\%}). CONCLUSION:: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.",
author = "Kim, {Gun Min} and Kim, {Young Sam} and {Ae Kang}, Young and Jeong, {Jae Heon} and Kim, {Sun Mi} and Hong, {Yun Kyoung} and Sung, {Ji Hee} and Lim, {Seung Taek} and Kim, {Joo Hang} and Kim, {Se Kyu} and Cho, {Byoung Chul}",
year = "2012",
month = "4",
day = "1",
doi = "10.1097/JTO.0b013e31824b23cb",
language = "English",
volume = "7",
pages = "731--736",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. / Kim, Gun Min; Kim, Young Sam; Ae Kang, Young; Jeong, Jae Heon; Kim, Sun Mi; Hong, Yun Kyoung; Sung, Ji Hee; Lim, Seung Taek; Kim, Joo Hang; Kim, Se Kyu; Cho, Byoung Chul.

In: Journal of Thoracic Oncology, Vol. 7, No. 4, 01.04.2012, p. 731-736.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients

AU - Kim, Gun Min

AU - Kim, Young Sam

AU - Ae Kang, Young

AU - Jeong, Jae Heon

AU - Kim, Sun Mi

AU - Hong, Yun Kyoung

AU - Sung, Ji Hee

AU - Lim, Seung Taek

AU - Kim, Joo Hang

AU - Kim, Se Kyu

AU - Cho, Byoung Chul

PY - 2012/4/1

Y1 - 2012/4/1

N2 - INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin- derivative antitumor agent that belongsto the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safetyof belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). METHODS:: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS:: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%). CONCLUSION:: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.

AB - INTRODUCTION: Belotecan (Camtobell, CKD602) is a new camptothecin- derivative antitumor agent that belongsto the topoisomerase inhibitors. The aim of this study was to evaluate the efficacy and safetyof belotecan monotherapy as a second-line therapy in patients with relapsed or refractory small cell lung cancer (SCLC). METHODS:: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS:: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%). CONCLUSION:: Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.

UR - http://www.scopus.com/inward/record.url?scp=84863344528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863344528&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31824b23cb

DO - 10.1097/JTO.0b013e31824b23cb

M3 - Article

C2 - 22425922

AN - SCOPUS:84863344528

VL - 7

SP - 731

EP - 736

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -